Compugen (CGEN) Non-Current Deffered Revenue (2013 - 2026)
Compugen (CGEN) posted quarterly Non-Current Deffered Revenue of $22.1 million for Q1 2026, down 30.31% year-over-year from $31.8 million in Q1 2025, and down 11.24% on a QoQ basis from $24.9 million in Q4 2025.
Compugen (CGEN) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Compugen has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $22.1 million in Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $22.1 million, down 30.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.1 million (down 30.31% YoY), and the FY2025 annual result was $24.9 million, down 26.74% from the prior year.
- Non-Current Deffered Revenue declined to $22.1 million in Q1 2026, from $24.9 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $34.0 million in Q4 2024 and troughed at $21.0 million in Q2 2024.
- A 4-year average of $26.9 million and a median of $26.5 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- The widest annual swing landed in 2025, when Non-Current Deffered Revenue jumped 40.73%; it then slumped 30.31% in 2026.
- A 4-year view of Non-Current Deffered Revenue shows it stood at $25.4 million in 2023, then surged by 34.08% to $34.0 million in 2024, then decreased by 26.74% to $24.9 million in 2025, then slipped by 11.24% to $22.1 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $22.1 million in Q1 2026, $24.9 million in Q4 2025, and $27.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | 22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.14 Mn |
| Dec 31, 2025 | 24.94 Mn |
| Sep 30, 2025 | 27.57 Mn |
| Jun 30, 2025 | 29.59 Mn |
| Mar 31, 2025 | 31.77 Mn |
| Dec 31, 2024 | 34.05 Mn |
| Sep 30, 2024 | 29.24 Mn |
| Jun 30, 2024 | 21.03 Mn |
| Mar 31, 2024 | 23.23 Mn |
| Dec 31, 2023 | 25.39 Mn |
| Jun 30, 2014 | 948,000.00 |
| Dec 31, 2013 | 1.45 Mn |